Great Lakes Advisors, LLC Dynavax Technologies Corp Transaction History

Great Lakes Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$13.09 - $14.98 $3.38 Million - $3.87 Million	-258,231 Reduced 34.57%	488,772 $6.83 Million
Q3 2023 Nov 07, 2023	BUY	$12.64 - $14.99 $9.29 Million - $11 Million	734,615 Added 5930.05%	747,003 $11 Million
Q2 2023 Aug 10, 2023	SELL	$9.85 - $13.17 $6.35 Million - $8.5 Million	-645,151 Reduced 98.12%	12,388 $160,000
Q1 2023 May 10, 2023	SELL	$9.44 - $11.88 $273,288 - $343,926	-28,950 Reduced 4.22%	657,539 $6.45 Million
Q4 2022 Feb 09, 2023	SELL	$10.27 - $13.29 $3.43 Million - $4.43 Million	-333,693 Reduced 32.71%	686,489 $7.3 Million
Q3 2022 Nov 09, 2022	SELL	$9.93 - $17.44 $271,803 - $477,367	-27,372 Reduced 2.61%	1,020,182 $10.7 Million
Q2 2022 Aug 09, 2022	BUY	$7.45 - $12.83 $7.61 Million - $13.1 Million	1,021,718 Added 3954.63%	1,047,554 $13.2 Million
Q1 2022 May 06, 2022	BUY	$9.75 - $14.44 $40,374 - $59,796	4,141 Added 19.09%	25,836 $280,000
Q4 2021 Feb 09, 2022	BUY	$13.17 - $20.94 $20,110 - $31,975	1,527 Added 7.57%	21,695 $305,000
Q3 2021 Nov 09, 2021	BUY	$9.16 - $19.83 $184,738 - $399,931	20,168 New	20,168 $387,000

257

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Great Lakes Advisors, LLC with notifications on news.